| MEDI | Wednesday, 13 September 2006 | ||
1:30 PM-5:00 PM Moscone Center -- Room 103, Oral | |||
Medicinal Chemistry of Rare Diseases | |||
| Organizers: | Jeffrey J. Ares Stephen C. Groft | ||
| 1:30 PM | Introductory Remarks | ||
| 1:45 PM | 319 | New kinase inhibitors for the treatment of hematological malignancies and gastrointestinal stromal tumors Paul W Manley, Sandra W. Cowan-Jacob, Doriano Fabbro, Jürgen Mestan | |
| 2:20 PM | 320 | New medicinal chemistry approaches to sickle cell disease Donald J. Abraham, Gajanan S. Joshi, Martin Safo | |
| 2:55 PM | 321 | Development of an oral prostacyclin analog (treprostinil diethanolamine) for the treatment of pulmonary arterial hypertension James P. Staszewski, Kenneth R Phares, David Mottola | |
| 3:30 PM | 322 | Calcium-sensing receptor modulators (calcimimetics) for the treatment of secondary hyperparathyroidism Andrew Tasker, David Martin | |
| 4:05 PM | 323 | Design and development of drugs to treat rare vancomycin resistant microbial pathogens Ramaiah Muthyala, James C Cloyd III, Gary M Dunny, Yuk Sham | |
| 4:25 PM | 324 | Clinical and regulatory considerations for rare disease therapy Marlene E. Haffner, Janet Whitley | |
Symposium Grid -- Division of Medicinal Chemistry -- Session Listing
Symposium Grid -- Drug Discovery -- Session Listing
The 232nd ACS National Meeting, San Francisco, CA, September 10-14, 2006